PPT-Diabetes Self-Care AADE 7 Self-Care Behaviors

Presented by Katie Spear MSN RNCDCES 3 Take away Points You have to learn how to take care of yourself Get all of the information that you can to help you stay healthy Make the time for your selfcare. DCE is comprised of members of the Academy of Nutrition and Dietetics who are leaders in the field of medical nutrition therapy and care of people with diabetes Their expertise is widely recognized throughout the diabetes community We are pleased to Neda. . Ratanawongsa. , MD, MPH. September 20, 2011. 2. Disclosures. Projects funded by:. AHRQ 5R21HS014864. AHRQ 5R18HS017261. McKesson Foundation. CDC Division of Diabetes Translation grant. California Diabetes Program. Researchers: Katie Cossette, MSOT/S’15. . Stacey . Dahm. , . MSOT/S’15. Stephanie Flower, . MSOT/S’15. Susan Goedeken, . MSOT/S’15. Merissa . Harkema. , OTD/S’16. Problem. Poor health behaviors are a significant contributor to illness and mortality.. PROVIDER TRAINING. LONG TERM SERVICES AND SUPPORTS. Brian Sandoval. Governor. Marta Jensen. Acting Administrator. Division of Health Care Financing and Policy. HISTORY OF THE BCCP. The Behaviorally Complex Care Program (BCCP) was established with the intention of providing care in Nevada for individuals with medically-based behavior disorders resulting in the Medicaid recipient posing a danger to self and/or others.. Board Certification . in Advanced . Diabetes . Management. Beverly . Dyck. Thomassian, RN, MPH, BC-ADM, CDE. President, Diabetes Education Services. www.DiabetesEd.net. © Copyright . 1999-2015, . Diabetes Educational Services, All Rights Reserved.. Efficacy and Safety of Antihyperglycemic Therapies Introduced Since 2004. 1. DPP-4 Inhibitors. 2. FDA-Approved Agents. Alogliptin. Linagliptin. Saxagliptin. Sitagliptin. Key Features. Oral administration. Disclosure. Robert Ratner has no disclosures.. Process. ADA’s Professional Practice Committee (PPC) conducts annual review & revision.. Searched Medline for human studies related to each subsection and published since January 1, 2015.. Efficacy and Safety of Modern Antihyperglycemic Therapies. 1. DPP-4 Inhibitors. 2. DPP-4 Inhibitors. FDA-Approved . Agents. Alogliptin. Linagliptin. Saxagliptin. Sitagliptin. Key . Features. Oral administration. J. Vassallo . (Malta). 15. th. MGSD Congress. 27-29 April, 2017. Organized by. Question. Do . you consider tight glycemic control . a. . priority . in management of type 2 diabetes. ?”. YES. Evidence Grading System. A. Clear evidence from well-conducted, generalizable RCTs, that are adequately powered, including:. Evidence from a well-conducted multicenter trial or meta-analysis that incorporated quality ratings in the analysis;. Number of deaths attributable to high blood glucose males females ages 30–69 630 ages 30–69 1 160 ages 70+ 340 ages 70+ 1 100 Operational policy/strategy/action plan for diabetes Evidence-based na the time of COVID- 19 . Professor . Vinod. Patel. FHEA FRCP MD MRCGP DRCOG . PSc. Professor, Diabetes and Clinical Skills. Hon Consultant in Endocrinology and Diabetes. Warwick Medical School, George Eliot Hospital NHS Trust, Nuneaton. Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP. Endocrine Clinical Pharmacy Specialist. CGM and Remote Monitoring Program Coordinator. Cleveland Clinic Endocrinology and Metabolist Institute. in YOUR Practice . . Katie Murphy. Diabetes Nurse . Facillitator. Diabetes In General Practice (DiGP). Where to start!. Register- How many patients require care. Quantifying the time required- 2 -3 visits per year.